Read by QxMD icon Read

III stage colon cancer

Dan Li, Chenhan Zhong, Xiujun Tang, Linzhen Yu, Kefeng Ding, Ying Yuan
PURPOSE: The extent to which ≥ 70 year patients with colon cancer benefit from adjuvant chemotherapy in the presence of competing risks remains controversial. METHODS: 18,937 patients ≥ 70 years with high-risk stage II and stage III colon cancer were retrospectively reviewed from SEER database. Propensity score matching (PSM) was used to adjust for potential baseline confounding. The nomograms were developed based on the competing model to describe the individual probability of colon cancer-specific death (CCSD) and non-CCSD...
February 19, 2018: Journal of Cancer Research and Clinical Oncology
Hee Jae Lee, Gyu-Seog Choi, Jun Seok Park, Soo Yeun Park, Hye Jin Kim, In Teak Woo, In Kyu Park
Purpose: We developed a technique of totally-robotic right colectomy with D3 lymphadenectomy and intracorporeal anastomosis via a suprapubic transverse linear port. This article aimed to introduce our novel robotic surgical technique and assess the short-term outcomes in a series of five patients. Methods: All colectomies were performed using the da Vinci Xi system. Four robot trocars were placed transversely in the supra pubic area. Totally-robotic right colectomy was performed, including colonic mobilization, D3 lymphadenectomy, and intra corporeal stapled functional anastomosis...
February 2018: Annals of Surgical Treatment and Research
A Sobrero, A Grothey, T Iveson, R Labianca, T Yoshino, J Taieb, T Maughan, M Buyse, T Andre, J Meyerhardt, A F Shields, I Souglakos, J-Y Douillard, A Cervantes
Background: Six months of adjuvant oxaliplatin-based chemotherapy is standard for patients with stage III colon cancer following surgery. However, oxaliplatin is associated with peripheral neurotoxicity which worsens over treatment duration. Consequently, a shorter treatment duration, if equally effective would be extremely beneficial. A pooled analysis of data for 12,834 stage III colon cancer patients, from six randomised phase III trials of adjuvant therapy, the IDEA study, was performed and the results presented at the ASCO Annual Meeting 2017...
February 9, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
A M Dinaux, L G J Leijssen, L G Bordeianou, H Kunitake, D L Berger
BACKGROUND: Screening for colorectal cancer has resulted in declining incidence rates of both colon and rectal cancer and it may influence stage at presentation and improve survival. The aim of this study was to assess the impact of screening on patients diagnosed with locally advanced rectal cancer. METHODS: A retrospective analysis of a consecutive series of patients who underwent neoadjuvant therapy and had an R0-resection for clinical AJCC stage II or stage III disease...
February 9, 2018: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
Matthew Alderdice, Susan D Richman, Simon Gollins, Peter Stewart, Chris Hurt, Richard Adams, Amy McCorry, Aideen Roddy, Dale Vimalachandran, Claudio Isella, Enzo Medico, Tim Maughan, Darragh G McArt, Mark Lawler, Philip D Dunne
Colorectal cancer (CRC) biopsies underpin accurate diagnosis, but are also relevant for patient stratification in molecularly-guided clinical trials. The consensus molecular subtypes (CMS) and colorectal cancer intrinsic subtypes (CRIS) transcriptional signatures have potential clinical utility for improving prognostic/predictive patient assignment. However, their ability to provide robust classification, particularly in pre-treatment biopsies from multiple regions or at different time points remains untested...
February 7, 2018: Journal of Pathology
Julia Richter, Anna-Laura Kretz, Johannes Lemke, Michael Fauler, Jens-Uwe Werner, Stephan Paschke, Frank Leithäuser, Doris Henne-Bruns, Andreas Hillenbrand, Uwe Knippschild
BACKGROUND: Colorectal cancer (CRC) is the fourth leading cause of cancer related deaths worldwide and prognosis in advanced tumor stage still remains poor. Since CK1 isoforms have been reported to be deregulated in several tumor entities CK1 has emerged as a novel drug target in cancer therapy. In this study we set out to investigate whether CK1α might have the potential to serve as prognostic marker. METHODS: CK1α RNA and protein expression levels in healthy and tumor tissue of CRC patients were analyzed using quantitative real-time PCR and Western Blot analysis, respectively...
February 6, 2018: BMC Cancer
Dianyu Yang, Wenqiang Quan, Junlu Wu, Xiaoyi Ji, Yan Dai, Weidong Xiao, Helen Chew, Zujun Sun, Dong Li
BACKGROUND: Red blood cell distribution width (RDW) is a parameter of standard full blood count tests that reflects the size variability of erythrocytes In recent studies, RDW levels have been associated with ischemic heart disease, acute and chronic heart failure, hypertension, and inflammatory bowel disease. However, it is unclear whether RDW is associated with colorectal cancer. METHODS: Eighty-five patients were diagnosed with colorectal cancer. Fifty-four other patients each diagnosed with colon polyps during the same period served as the control group...
February 1, 2018: Clinica Chimica Acta; International Journal of Clinical Chemistry
Pierre Michel, Valerie Boige, Thierry Andre, Thomas Aparicio, Jean Baptiste Bachet, Laetitia Dahan, Rosine Guimbaud, Côme Lepage, Sylvain Manfredi, David Tougeron, Julien Taieb, Janick Selves, Karine Le Malicot, Frederic Di Fiore, Emilie Maillard
Oxaliplatin-based adjuvant chemotherapy is standard of care for radically resected stage III colon cancer and an accepted option for high-risk stage II. Two recent retrospective studies strongly suggested that low-dose aspirin used (100 mg/d) after surgical resection of colorectal cancer with a PIK3CA mutation could act as a targeted therapy with a major protective effect on the risk of recurrence. We propose a double-blind randomized phase III study to evaluate aspirin (100 mg/d during 3 years or until recurrence) versus placebo...
December 30, 2017: Digestive and Liver Disease
Felix J Hüttner, Rene Warschkow, Bruno M Schmied, Markus K Diener, Ignazio Tarantino, Alexis Ulrich
BACKGROUND: There is limited information regarding the impact of anastomotic leakage on oncologic outcome in exclusively colon cancer patients. METHODS: The colorectal database of the Department of Surgery of the University of Heidelberg was used to assess the impact of anastomotic leakage on oncologic outcome in patients undergoing curative resection for Stage I-III colon cancer. Risk-adjusted Cox regression analysis and propensity score methods were used to assess overall, disease-free, and relative survival...
January 30, 2018: European Journal of Surgical Oncology
Sayaka Amano, Susumu Shibasaki, Shinpei Furuta, Shinichi Kadoya, Kenji Kikuchi, Yoshinori Ishida, Kazuki Inaba, Ichiro Uyama
A 76-year-old woman, complained of weight loss, was admitted in our hospital. After investigation, she was diagnosed with clinical Stage III B gastric cancer with invasion into the pancreas and transverse colon. After performing the staging laparoscopy and gastrojejunostomy for pyloric stenosis, she was treated with 2 courses of SOX therapy as neoadjuvant therapy, and subsequently underwent pancreaticoduodenectomy and right hemicolectomy combined with portal vein resection due to severe adhesion by the tumor...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Takahiro Akiyama, Jun Yasutomi, Kimihiko Kusashio, Masanari Matsumoto, Takeshi Suzuki, Ayako Iida, Namiko Imamura, Arihito Yoshizumi, Rina Harano, Ikuo Udagawa, Masayuki Ohtsuka
We report a case of a 79-year-old man who developed severe therapy-related pancytopenia from tegafur uracil(UFT)and Leucovorin(LV)as adjuvant chemotherapy for ascending colon cancer. Laparoscopic right hemicolectomy resection was performed for the ascending colon cancer. Pathohistological analysis revealed that the ascending colon tumor was moderately differentiated tubular adenocarcinoma(T3, N1, M0, and Stage III a). Postoperative adjuvant chemotherapy with UFT and LV was administered. After 2 courses of chemotherapies, severe thrombocytopenia(Grade 4)and neutropenia(Grade 4)were noted...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Keishi Hakoda, Masanori Yoshimitsu, Manabu Emi, Yuya Hirai, Atsushi Kamigaichi, Manato Osawa, Norimasa Kuraoka, Toshiaki Komo, Norifumi Tsubokawa, Ichiko Yamakita, Masashi Miguchi, Yoshiro Aoki, Akira Nakashima, Mikihiro Kano, Koichi Oishi, Toshihiko Kohashi, Mayumi Kaneko, Mahito Funakoshi, Jun Hihara, Hidenori Mukaida, Naoki Hirabayashi
Anal metastasis of colorectal cancer is rare, and no standardized effective therapeutic strategy exists. We report a case of abdominoperineal resection for anal metastasis of rectal cancer. A 65-year-old man underwent laparoscopic low anterior resection for rectal cancer in August 2013. Histopathological examination revealed a moderately differentiated adenocarcinoma( tub2, pSS, ly3, v2, pN1, H0, P0, M0, Stage III a, Cur A). In February 2015, he complained of anal discomfort, and tumor markers were elevated...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Tomohiko Machida, Kunihiko Hiraoka, Nagahide Matsubara
The patient was a 73-year-old woman who received surgery for transverse colon cancer(laparoscopic right hemicolectomy) in December 2014. Histopathologic examination findings were tub2, pT4b, pN1, sH0, sM0, ly2, v0, Stage III a. XELOX 2 courses→FOLFIRI plus panitumumab(Pmab)12 courses was performed after surgery. Stenosis due to duodenum dissemination was observed in the follow-up period(December 2015), and a laparoscopic gastrojejunostomy was performed. Later, the patient's tumor marker value significantly increased, and enlargement of duodenum dissemination was observed by abdominalCT...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Justin C Brown, Nevena Damjanov, Kerry S Courneya, Andrea B Troxel, Babette S Zemel, Michael R Rickels, Bonnie Ky, Andrew D Rhim, Anil K Rustgi, Kathryn H Schmitz
OBJECTIVE: To examine the dose-response effects of aerobic exercise on health-related quality of life (HRQoL) among colon cancer survivors. METHODS: Thirty-nine stage I-III colon cancer survivors were randomized to one of three groups: usual-care control, 150 min·wk-1 of aerobic exercise (low-dose), and 300 min·wk-1 of aerobic exercise (high-dose) for six months. HRQoL outcomes included the Short Form (SF)-36 physical and mental component summary, Functional Assessment of Cancer Therapy-Colorectal (FACT-C), Pittsburgh Sleep Quality Index (PSQI), Fear of Cancer Recurrence Inventory (FCRI), Fatigue Symptom Inventory (FSI), and North Central Cancer Treatment Group bowel function questionnaire, assessed at baseline and post intervention...
February 1, 2018: Psycho-oncology
Dehao Yu, Peng Gao, Yongxi Song, Yuchong Yang, Xiaowan Chen, Yu Sun, Ailin Li, Zhenning Wang
Until now, it remains unclear how to best use the histological subtype in clinical practice. This study aimed to compare differences in the efficacy of postoperative chemotherapy among different histological subtypes of colon adenocarcinomas. Using the Surveillance, Epidemiology, and End Results-Medicare database, 51,200 patients with stage II or III primary colon carcinomas who underwent resection for curative intent between 1992 and 2008 were included. The survival benefit was evaluated using a Cox proportional hazards model, interaction analyses, and propensity score-matched techniques...
January 29, 2018: Cancer Medicine
Megan C Turner, Norma E Farrow, Kristen E Rhodin, Zhifei Sun, Mohamed A Adam, Christopher R Mantyh, John Migaly
BACKGROUND: Adjuvant chemotherapy following resection is the standard of care for stage III colon cancer, yet many patients omit chemotherapy. We aim to describe the impact of delayed chemotherapy on overall survival across multiple time points. STUDY DESIGN: The 2006-2014 National Cancer Data Base (NCDB) was queried for patients with single primary stage III adenocarcinoma of the colon. Patients were grouped by receipt and timing of chemotherapy from resection date: chemotherapy omitted, <6 weeks, 6-8 weeks, 8-12 weeks, 12-24 weeks, and >24 weeks...
January 26, 2018: Journal of the American College of Surgeons
Weixing Dai, Yaqi Li, Shaobo Mo, Yang Feng, Long Zhang, Ye Xu, Qingguo Li, Guoxiang Cai
Colon cancer patients experiencing early relapse consistently exhibited poor survival. The aim of our study was to develop an mRNA signature that can help to detect early relapse cases in stage I-III colon cancer. Public microarray datasets of stage I-III colon cancer samples were extracted from the Gene Expression Omnibus database. Propensity score matching analysis was performed between patients in the early relapse group and the long-term survival group from GSE39582 discovery series (N=386) and patients were 1:1 matched...
January 27, 2018: Molecular Oncology
Karis Kin-Fong Cheng, Ethel Yee-Ting Lim, Ravindran Kanesvaran
OBJECTIVES: The measurement of quality of life (QoL) in elderly cancer population is increasingly being recognised as an important element of clinical decision-making and the evaluation of treatment outcome. This systematic review aimed to summarise the evidence of QoL during and after adjuvant therapy in elderly patients with cancer. METHODS: A systematic search was conducted of studies published in CINAHL plus, CENTRAL, PubMed, PsycINFO and Web of Science from the inception of these databases to December 2016...
January 24, 2018: BMJ Open
Hiroyuki Ishiodori, Koichi Doi, Fumimasa Kitamura, Norio Uemura, Takeyoshi Kaida, Tetsufumi Ohchi
A 62-year-old man was underwent sigmoidectomy for sigmoid colon cancer(T3N1H0P0, Stage III a). He received a postoperative systemic chemotherapy with SOX. Five months after the operation, multiple liver metastases were detected by CT scan. Systemic chemotherapy(bevacizumab and SOX, bevacizumab and FOLFIRI)did not reduce the liver metastases. So 4 courses of hepatic arterial infusion(HAI)chemotherapy with CDDP 10mg/day and 5-FU 500mg/day for 2weeks were performed without severe adverse events. All the liver metastases decreased in size remarkably, and the hepatic resection was able to be performed...
January 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Ichiro Higuchi, Yosuke Akiyama, Akira Ishikawa, Sanae Hosomi, Takahiko Tanigawa, Yasunori Hasuike, Makoto Miyamoto
We treated 2 cases ofcolon metastasis ofgastric cancer considered to be caused by different pathway. Case 1 was a 55- year-old male with gastric cancer associated with metastases for lymph node, gallbladder, and liver. Curative surgical treatment of distal gastrectomy, partial hepatectomy, cholecystectomy and lymph node dissection was performed. The final find- ing was, L, Less, Type 3, pT4b(GB), tub2, pN3a(10/20), sP0, CY0, pH1, pM1, Stage IV , R0. Ten months after, ileocecal resection was performed, as a tumor was detected in the cecum...
January 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"